<DOC>
	<DOCNO>NCT01989468</DOCNO>
	<brief_summary>The purpose study provide 24 - 52 week efficacy , safety tolerability data , well 3-year efficacy , safety tolerability data subject active Psoriatic Arthritis despite current previous nonsteroidal anti-inflammatory drug ( NSAID ) , disease-modifying antirheumatic drug ( DMARD ) therapy and/or previous anti-tumor necrosis factor alpha ( TNFα ) therapy .</brief_summary>
	<brief_title>24 Week Efficacy 3-year Safety Efficacy Secukinumab Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis Psoriatic Arthritis ( PsA ) classify ClASsification criterion Psoriatic ARthritis ( CASPAR ) criterion . Rheumatoid factor anticyclic citrullinated peptide ( CCP ) antibodies negative . Diagnosis active plaque psoriasis nail change consistent psoriasis . Inadequate control symptom NSAID . Chest Xray chest magnetic resonance imaging ( MRI ) evidence ongoing infectious malignant process . Subjects take high potency opioid analgesic . Previous exposure secukinumab biologic drug directly target interleukin17 ( IL17 ) IL17 receptor . Ongoing use prohibit psoriasis treatment / medication . Subjects ever receive biologic immunomodulating agent except target TNFα . Previous treatment celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>AIN457</keyword>
	<keyword>PsA</keyword>
	<keyword>ACR</keyword>
	<keyword>CASPAR</keyword>
	<keyword>PASDAS</keyword>
	<keyword>secukinumab</keyword>
	<keyword>autoinjector</keyword>
</DOC>